Drug name - Zulresso

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635773 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9200088 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9750822 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US8410077 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US10117951 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US10322139 SAGE THERAP Neuroactive steroid formulations and methods of treating CNS disorders Jan, 2033

(10 years from now)

US10251894 SAGE THERAP Anticonvulsant activity of steroids Nov, 2033

(11 years from now)

US10940156 SAGE THERAP Neuroactive steroids, compositions, and uses thereof Mar, 2037

(14 years from now)

Drugs and Companies using BREXANOLONE ingredient

Treatment: Method of treating postpartum depression

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/20ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.